ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1188

Diabetes Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting

Kate Orroth1, Cristi Cavanaugh2, Xi Qian2, Pam Kumparatana2, Yuri Klyachkin3, Stephen Colgan4 and Myriam Cordey4, 1Amgen, Manhattan Beach, CA, 2OM1, Inc., Boston, MA, 3Amgen, Lexington, KY, 4Amgen, Inc., Thousand Oaks, CA

Meeting: ACR Convergence 2022

Keywords: Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with PsO and PsA have a higher prevalence of cardiometabolic comorbidities like diabetes compared to the general population. Clinical data have shown apremilast may reduce weight and HbA1c. We describe changes in cardiometabolic parameters and disease activity outcomes over a 6-month follow-up period among PsO and PsA patients stratified by diabetes status and newly treated with apremilast using a large, United States-based real-world cohort.

Methods: We estimated the burden of diabetes among PsO and PsA patients in the OM1 Real-World Data Cloud newly initiating apremilast and persistent for 6 months. These data spanned from March 2013 to November 2021. We stratified the study cohort by diabetes status (no diabetes vs pre-diabetes/type 2 diabetes mellitus [T2DM]). Pre-diabetes was identified by either 2 diagnosis codes at least 30 days apart, HbA1c levels between 5.7% to 6.4%, or fasting glucose levels between 100-125 mg/dL. T2DM was defined as having two diagnosis codes at least 30 days apart or evidence of antidiabetic medication during baseline.

We described demographic and clinical characteristics, comorbidities, and treatments at baseline, assessed changes in weight and HbA1c, and disease activity measures (RAPID3 and Physician Global Assessment [PGA]) at 6 months. We used Wilcoxon Rank sum tests and Chi-square tests for comparisons by diabetes status. Mean proportional changes in cardiometabolic measures and disease severity at 6 months were estimated. Multivariable linear regression was used to assess cardiometabolic measures, adjusting for age, sex, use of anti-hypertensives, lipid-lowering therapies, steroids, and corresponding baseline outcomes.

Results: There were 8,487 PsO and PsA patients with outcome measures that initiated apremilast. The mean age was 55.2 years and 62.8% were female. 23.6% (2,004) had pre-diabetes /T2DM. 87.1% (1,746) had T2DM and 12.9% had pre-diabetes. These patients were older (59 vs. 54, p < 0.001), with higher proportions of patients identifying as Black (4.1% vs. 2.3%, p < 0.001) and Hispanic (5.7% vs. 3.6%, p < 0.001) compared to those without diabetes. Most patients were obese (26.2%) or severely obese (32.6%) (Table 1). Comorbidities were prevalent in the diabetes group, with 28.3% having two or more. Prevalent comorbidities included hypertension (38.4%), dyslipidemia (31.4%), and cardiovascular disease (13.4%) (Table 2). Patient and physician outcomes at baseline reflected mild to moderate disease severity. Mean raw RAPID3 score was higher among those with diabetes (13.49 vs. 11.20, p = 0.047), while mean PGA (2.81 vs. 2.77) was similar across strata. We observed reductions in weight, HbA1c and disease severity outcomes at 6 months regardless of diabetes status (Figure 1).

Conclusion: This real-world study highlights the significant cardiometabolic burden among PsO and PsA patients who initiated apremilast. Similar to the clinical trials data, this study suggests apremilast may have beneficial effects on cardiometabolic markers in clinical practice including reductions in weight, HbA1c, and improvements in PsO/ PsA disease outcomes.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: K. Orroth, Amgen; C. Cavanaugh, None; X. Qian, None; P. Kumparatana, OM1; Y. Klyachkin, Amgen; S. Colgan, Amgen; M. Cordey, Amgen.

To cite this abstract in AMA style:

Orroth K, Cavanaugh C, Qian X, Kumparatana P, Klyachkin Y, Colgan S, Cordey M. Diabetes Burden and Effects of Apremilast on Changes in Cardiometabolic Parameters in Patients with Psoriasis (PsO) or Psoriatic Arthritis (PsA) in a Real-World Setting [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/diabetes-burden-and-effects-of-apremilast-on-changes-in-cardiometabolic-parameters-in-patients-with-psoriasis-pso-or-psoriatic-arthritis-psa-in-a-real-world-setting/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diabetes-burden-and-effects-of-apremilast-on-changes-in-cardiometabolic-parameters-in-patients-with-psoriasis-pso-or-psoriatic-arthritis-psa-in-a-real-world-setting/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology